September 2021 Digital Edition

Tag: topical foam

Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions

March 1, 2021

J Clin Aesthet Dermatol. 2021;14(3):E53–E57. by Terry M. Jones, MD, and Iain Stuart, PhD Dr. Jones is with J&S Studies Inc., in College Station, Texas. Dr. Stuart is with VYNE Therapeutics Inc., in Bridgewater, New Jersey. FUNDING: This study was sponsored by Foamix Pharmaceuticals Ltd., a wholly owned subsidiary of VYNE Therapeutics Inc. DISCLOSURES: Dr.